The Oncology Institute, Inc.
NASDAQ:TOIMedical - Care Facilities
-$0.07 today
- Market cap
- $512.91M
- Beta
- 0.41
- P/E (TTM)
- -121.1
- EPS (TTM)
- -$0.04
Volume 1.21M
Average 1.74M
TOI Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
The Oncology Institute, Inc.NASDAQ: TOI
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables declines year over year
Q1 FY2026 accounts receivables of $130K (cash outflow) fell 86.8% year over year, ahead of the -223.9% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -13.8% a year.
Context
- Accounts receivables amounted to 2.5% of revenue in FY2025, up 1.0 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -86.8% holds above the trailing-twelve-month pace of -223.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (12.58M) USD
- Year-over-year change
- -118.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.58M) | -118.1% |
| FY2024 | 2024-12-31 | (5.77M) | -28.3% |
| FY2023 | 2023-12-31 | (4.5M) | +77.1% |
| FY2022 | 2022-12-31 | (19.67M) | -558.4% |
| FY2021 | 2021-12-31 | (2.99M) | — |
Accounts Receivables vs competitors
How TOI compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -223.9% is the lowest of 9, against a peer median of +1.3%.
- Accounts receivables amounts to 2.1% of revenue for TOI, versus a peer median of 2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AUNAAuna S.A. | LTM Mar 2026 | PEN 50.57M PEN | -83.0% | -1.5% | 1.1% |
| LTM Mar 2026 | $44.1M USD | +257.7% | — | 4.4% | |
| LTM Mar 2026 | $13.46M USD | -6.1% | — | 14.5% | |
| LTM Mar 2026 | $11.73M USD | -223.9% | -13.8% | 2.1% | |
| LTM Mar 2026 | $8.53M USD | -48.4% | +7.0% | 2.8% | |
| LTM Mar 2026 | $8.05M USD | +8.8% | +33.0% | 3.3% | |
| LTM Mar 2026 | $7.32M USD | -18.8% | +8.1% | 1.8% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $4.33M USD | +27.2% | +1.8% | 4.6% |
| LTM Mar 2026 | $306K USD | +107.3% | -42.6% | 0.1% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding TOI) | — | +1.3% | +4.4% | 2.8% | |
Competitors are the stored peer set for TOI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.93M) | 152K | (83.07M) | (53.01M) | (60.61M) |
| Depreciation & Amortization | 3.34M | 4.41M | 5.87M | 6.29M | 6.94M |
| Deferred Income Tax | (1.24M) | (263K) | (76K) | 0 | (32K) |
| Stock-Based Compensation | 24.54M | 27.68M | 17.81M | 11.15M | 4.55M |
| Change in Working Capital | (14.49M) | (20.54M) | 2.36M | 18.06M | 1.33M |
| Accounts Receivables | (2.99M) | (19.67M) | (4.5M) | (5.77M) | (12.58M) |
| Inventory | (1.84M) | (1.73M) | (4.39M) | 3.64M | (6.84M) |
| Accounts Payables | 2.92M | (6.19M) | 5.06M | 9.22M | 19.64M |
| Other Working Capital | (12.58M) | 7.04M | 6.19M | 10.98M | 1.11M |
| Other Non-Cash Items | (33.9M) | (73.2M) | 20.79M | 2.12M | 23.23M |
| Operating Cash Flow | (32.68M) | (61.76M) | (36.32M) | (26.54M) | (24.59M) |
| Capital Expenditures | (3.05M) | (5.53M) | (4.57M) | (3.79M) | (3.2M) |
| Acquisitions (Net) | (9.11M) | (8.58M) | (4.46M) | 0 | 0 |
| Purchases of Investments | 0 | (117.51M) | (9.6M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 81.26M | 50M | 126K |
| Other Investing Activities | (200K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (12.15M) | (131.61M) | 62.64M | 46.21M | (3.07M) |
| Debt Repayment | (7.25M) | 109.94M | (101K) | (39K) | (20.04M) |
| Common Stock Issued | 0 | 0 | 0 | 75K | 32.63M |
| Common Stock Repurchased | 0 | (9M) | (1.02M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 141.26M | (8.74M) | (5.73M) | (3.53M) | (1.04M) |
| Financing Cash Flow | 154.01M | 92.21M | (6.85M) | (3.49M) | 11.56M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 109.18M | (101.16M) | 19.48M | 16.18M | (16.1M) |
| Free Cash Flow | (35.73M) | (67.29M) | (40.88M) | (30.33M) | (27.79M) |
The Oncology Institute, Inc.
NASDAQ:TOI
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.